Validation of an Age-adjusted Prostate Cancer-Specific Comorbidity Index.

Estimating competing mortality is of paramount importance for prostate cancer screening candidates and men with early prostate cancer. An age-adjusted prostate cancer-specific comorbidity index (PCCI) was developed recently for this purpose in an unselected population of 1598 men.

We validated this mortality index in a sample of 2961 patients who consecutively underwent radical prostatectomy between 1992 and 2007 at our institution. In patients with a PCCI of 0, 1-2, 3-4, 5-6, 7-9, and ≥10 who were selected for radical prostatectomy, the 10-yr competing mortality rates were 2%, 9%, 17%, 27%, 56%, and 0% (n=3), respectively, compared with 10%, 19%, 35%, 60%, 79%, and 99%, respectively, in the unselected development cohort. The PCCI is well suited to stratify patients with prostate cancer according to their risk of competing mortality. In candidates for radical prostatectomy, however, the 10-yr competing mortality rates are approximately half as high as in unselected patients with the same PCCI risk level.

With stratification by the age-adjusted prostate cancer-specific comorbidity index, the 10-yr competing mortality rate in men selected for radical prostatectomy is approximately half as high as in unselected patients at the same level of comorbid risk.

European urology. 2015 Nov 08 [Epub ahead of print]

Michael Froehner, Rainer Koch, Matthias Hübler, Manfred P Wirth

Department of Urology, University Hospital "Carl Gustav Carus," Technische Universität Dresden, Dresden, Germany. Department of Medical Statistics and Biometry, University Hospital "Carl Gustav Carus," Technische Universität Dresden, Dresden, Germany. , Department of Anesthesiology, University Hospital "Carl Gustav Carus," Technische Universität Dresden, Dresden, Germany. , Department of Urology, University Hospital "Carl Gustav Carus," Technische Universität Dresden, Dresden, Germany.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe